VASCULARIZATION OF MANY SOLID TUMORS OCCURS IN VIVO AS A CONSEQUENCE OF THE VECTORIAL GROWTH OF HOST CAPILLARY ENDOTHELIAL CELLS ALONG A CONCENTRATION GRADIENT OF TUMOR- PRODUCED, DIFFUSIBLE ANGIOGENESIS FACTOR(S).

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 4723
Amount: $50,000.00
Phase: Phase I
Program: SBIR
Awards Year: 1986
Solicitation Year: N/A
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
Angiogen
107 Lakefront Drive, Hunt Valley, MD, 21030
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 ALLAN H FENSELAU
 PRINCIPAL INVESTIGATOR
 (301) 667-6880
Business Contact
Phone: () -
Research Institution
N/A
Abstract
VASCULARIZATION OF MANY SOLID TUMORS OCCURS IN VIVO AS A CONSEQUENCE OF THE VECTORIAL GROWTH OF HOST CAPILLARY ENDOTHELIAL CELLS ALONG A CONCENTRATION GRADIENT OF TUMOR- PRODUCED, DIFFUSIBLE ANGIOGENESIS FACTOR(S). THE IDENTIFICATION OF ONE OF THESE FACTORS AS "ANGIOGENIC COPPER" RAISES THE POSSIBILITY THAT COPPER CHELATORS CAN FUNCTION AS ANTIANGIOGENIC AGENTS. THE SPECIFIC AIMS OF THIS PHASE I STUDY ARE: (1) TO TEST VARIOUS COPPER CHELATORS FOR POSSIBLE ANTIANGIOGENIC EFFECTS IN THE CHICKENCHORIOALLANTOIC MEMBRANE (CAM) ASSAY; (2) TO EMPLOY AS ANGIOGENIC STIMULATORS IN THIS SYSTEM (A) COPPER-HEPARIN, A POLYPEPTIDE ANGIOGEN DERIVED FROM NERVOUS TISSUES; (B) A LOWMOLECULAR WEIGHT ANGIOGEN DERIVED FROM THE WALKER 256 RAT TUMOR; AND (C) VIABLE TUMOR CELLS FROM THIS SAME SOURCE; (3) TO ESTABLISH, USING IN VITRO METHODS, WHETHER AGENTS ACTIVE IN THE CAM ASSAY ARE INHIBITING VASCULAR ENDOTHELIAL CELL (EC) MIGRATION AND/OR PROLIFERATION OR ARE TOXIC TO EC AND/OR TUMOR CELLS; AND (4) BASED ON THE OUTCOME OF THE STUDIES RELATED TO THE FIRST THREE OBJECTIVES, TO PREPARE HEPARIN-(OR HEPARIN FRAGMENT) LINKED CHELATORS AND EMPLOY THESE NOVEL SUBSTANCES IN ANALOGOUS STUDIES. RESULTS FROM THESE STUDIES SHOULD ALLOW INDENTIFICATION OF NEW ANTI- ANGIOGENIC AGENTS. THESE SUBSTANCES CAN THEN BE SCREENED MORE THOROUGHLY IN A PHASE II STUDY FOR THEIR ANTICANCER PROPERTIES AGAINST VARIOUS TUMORS IN EXPERIMENTAL ANIMALS. THUS, THE ULTIMATE OBJECTIVE OF THESE STUDIES IS TO DEFINE NOVEL ANTIANGIOGENIC AGENTS THAT WILL PROVIDE IMPROVED MEANSFOR CONTROLLING TUMOR GROWTH AND SPREAD.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government